Movatterモバイル変換


[0]ホーム

URL:


CN104027306A - Paroxetine oral suspension and preparation method thereof - Google Patents

Paroxetine oral suspension and preparation method thereof
Download PDF

Info

Publication number
CN104027306A
CN104027306ACN201410287053.6ACN201410287053ACN104027306ACN 104027306 ACN104027306 ACN 104027306ACN 201410287053 ACN201410287053 ACN 201410287053ACN 104027306 ACN104027306 ACN 104027306A
Authority
CN
China
Prior art keywords
salt
paroxetine
mixed suspension
oral administration
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410287053.6A
Other languages
Chinese (zh)
Inventor
浦洁
郭夏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEIJING D-VENTUREPHARM TECHNOLOGY DEVELOPMENT Co Ltd
Aventis Pharma Hainan Co Ltd
Original Assignee
BEIJING D-VENTUREPHARM TECHNOLOGY DEVELOPMENT Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEIJING D-VENTUREPHARM TECHNOLOGY DEVELOPMENT Co LtdfiledCriticalBEIJING D-VENTUREPHARM TECHNOLOGY DEVELOPMENT Co Ltd
Priority to CN201410287053.6ApriorityCriticalpatent/CN104027306A/en
Publication of CN104027306ApublicationCriticalpatent/CN104027306A/en
Pendinglegal-statusCriticalCurrent

Links

Landscapes

Abstract

The invention discloses oral suspension containing medicine resin salt of Paroxetine and salts of Paroxetine. The oral suspension is an antidepressant, is stable in property and is good in taste.

Description

Paroxetine oral administration mixed suspension and preparation method thereof
Technical field
The invention belongs to field of pharmaceutical preparations, more relate to a kind of oral mixed suspension solution of the medical resin salt that comprises paroxetine (Paroxetine) and salt thereof, its stable in properties and there is good mouthfeel.
Background technology
Paroxetine (Paroxetine), its chemical name is:(-)-trans-4R-(4-fluorophenyl)-3S-{[3 ', 4 '-(methylene-dioxy) phenoxy group] methyl }-piperidines(1:1) salt acid-addition salts.Be usually used in clinically depression and compulsive treatment.
Paroxetine is the antidepressants of a kind of selective serotonin reuptake inhibithors (SSRI) type, its drug form is paroxetine hydrochloride (Paroxetine hydrochloride), commodity " seroxat " by name ordinary tablet (Seroxat), it is a kind of high selectivity serotonin reuptake inhibitor, by what stop 5-hydroxy tryptamine, absorb again the concentration that improves 5-hydroxy tryptamine in nerve synapse gap, enhancing maincenter 5-hydroxy tryptamine function of nervous system, thus antidepressant effect produced.
This compound is used for human body by approval, and as the many countries sale in the whole world of a kind of antidepressant preparation.Paroxetine listing dosage form is mainly oral tablet at present, yet some patient for example: child and old man are taking the problem that often runs into dysphagia, therefore need to develop the row of being obedient to that oral liquid improves patient.But because paroxetine has very strong bitterness, during with drink form, this bitterness is obvious especially, secondly, stability of Oral is poor, and effect duration is short.So be prepared into suspension, can not only effectively cover bitterness, can also increase greatly the stability of preparation, improve effect duration.
Summary of the invention
The present invention discloses a kind of stable in properties, the good oral administration mixed suspension of mouthfeel, and described suspension comprises effective ingredient(-)-trans-4R-(4-fluorophenyl)-3S-{[3 ', 4 '-(methylene-dioxy) phenoxy group] methyl }-piperidinesand the medical resin salt of salt and Amberlite series plastics, described suspension is included in this suspension and adds suspending agent, antiseptic, and correctives, and its acid-base value is adjusted between pH3-8.
The present invention coordinates Amberlite series plastics formation medical resin with paroxetine, and adds aerosil to be prepared into suspension, and adds antiseptic, can effectively improve the stability of preparation.At propylene glycol: prepare medical resin salt in water (1:1) medium standby, high temperature 70-80 ℃ aqueous medium adds preservative and sweetener, adds suspending agent under stirring condition, and the cooling medical resin salt that adds, obtains oral administration mixed suspension to be prepared next time.
Wherein (-)-trans-4R-(4-fluorophenyl)-3S-{[3 ', 4 '-(methylene-dioxy) phenoxy group] methyl } the medicine and pharmacology acceptable addition salt of-piperidines is 1:1 salt acid-addition salts.
Wherein the mol ratio of Amberlite and paroxetine is 1:2-2:1.
Wherein Amberlite series plastics is weak-acid cation-exchange resin, is selected from Amberlite IRP-88, wherein one or more of Amberlite IRP-64 and Amberlite IRP-69.Amberlite series weak-acid cation-exchange resin can coordinate with medicine formation medical resin, effectively covers the bitterness of medicine.
The antiseptic that described paroxetine oral administration mixed suspension comprises is benzoic acid, and its concentration, between 0.1mg/mL to 2 mg/mL, is damaged oral administration mixed suspension in order to prophylaxis of microbial.
Wherein pharmaceutically acceptable sweetener packets contains the preferably sweeting agent of at least one reinforcement, for example: glucide, saccharin sodium and calcium, aspartame, Ai Si divide potassium, cyclamate, acesulfame potassium, LaspartylLphenylalanine methylester, encircle dithiocarbamic acid sodium, Ali is sweet, dihydro is looked into ketone, Mo Lin, Flos Chrysanthemi essence, 1,4,6-sucralose, acesulfame potassium, preferably is saccharin sodium.The bulk sweetener needing, such as: Sorbitol, mannitol, fructose, sucrose, maltose, lactose, glucose, xylitol etc.
The sweeting agent of strengthening is generally used under low concentration, and for example the concentration of saccharin sodium is between 0.01% to 0.1%w/v, and preferably approximately 0.05%.Bulk sweetener, for example Sorbitol can be effectively for relatively large scope, and approximately 30% to 50%w/v, and preferably approximately 40%.
Essence pharmaceutically acceptable, that can cover bitter principle, preferably is fruit-like flavour, for example: Fructus Pruni pseudocerasi, honey peach, Fructus Fragariae Ananssae, orange taste, Herba Menthae local flavor, hami melon etc. are at pharmaceutically acceptable strong taste essence.Preferably essence concentration between 0.05% to 1%w/v.The combination of this strong taste spice of use that can be favourable, preferably makes its sense of taste and color under the acid condition of formula not have any change or forfeiture, and does not affect the character of other compositions in formula while using spice.
specific embodiment:
1mol paroxetine hydrochloride is joined to a certain amount of propylene glycol with the AmberliteIRP-64 of 0.5,1,2mol respectively: in water (1:1) solution, as for allowing toner be dispersed in solution in water bath with thermostatic control agitator, shaken overnight under room temperature.Adopt vacuum filter by resin salt and fluid separation applications, afterwards by a small amount of water cleaning resin salt three times, the resin after sucking filtration is placed on the medical resin salt that dried overnight in 60 degrees Celsius of vacuum drying ovens obtains paroxetine.
The oral liquid of the paroxetine-AmberliteIRP-64 medical resin salt that contains different mol ratio according to table 1 preparation, selects 10 volunteers to evaluate bitterness by blind method research oral administration mixed suspension at random, is recorded as 1 to 5 minute.The taste masking effect of assessment AmberliteIRP-64 to paroxetine.
The impact of table 1 AmberliteIRP-64 consumption on mouthfeel
CompoundPrescription 1Prescription 2Prescription 3
Medical resin salt2:11:11:2
Microcrystalline Cellulose CL61130 mg/mL30 mg/mL30 mg/mL
Orange taste essence1mg/mL1mg/mL1mg/mL
Sorbitol 70%(w/v)400mg/mL400mg/mL400mg/mL
Methyl parahydroxybenzoate0.5mg/mL0.5mg/mL0.5mg/mL
Propyl p-hydroxybenzoate0.5mg/mL0.5mg/mL0.5mg/mL
The affect result of table 2 AmberliteIRP-64 consumption on mouthfeel
ExperimenterPrescription 1Prescription 2Prescription 3
A134
B323
C244
D333
E333
F123
G232
H224
I343
J443
Average score2.433.2
Note: 5-mouthfeel is very good, and 4-mouthfeel is better, and 3-mouthfeel is general, and 1-mouthfeel is bad
When the mol ratio of paroxetine and AmberliteIRP-64 is 1:1, can play the effect of significantly covering bitterness.When the consumption of AmberliteIRP-64 continues to increase the effect that has not improved significantly.So select paroxetine: the medical resin salt that the ratio of AmberliteIRP-64 is 1:1.In order further to improve mouthfeel, intend regulating kind and the consumption of correctives in prescription.
Embodiment 2: comparative study
2 kinds of essence (orange taste essence and strawberry essence) and two kinds of sweeting agents (Sorbitol 70%(w/v) and saccharin sodium merge are used in assessment) after the taste of feeling and pleasant impression.10 volunteers of random selection evaluate its sugariness, fruity, the sensations such as bitterness by blind method research to including the oral mixed suspension formula of liquid (as shown in table 2) of one of two kinds of spice.
The impact on mouthfeel of table 3 sweeting agent and essence
CompoundPrescription 1Prescription 2Prescription 3Prescription 4
Orange taste essence (mg/mL)0.51.5??
Strawberry essence (mg/mL)--0.51.5
Sorbitol 70%(w/v) (mg/mL)300500300500
Saccharin sodium (mg/mL)0.50.51.01.0
Methyl parahydroxybenzoate (mg/mL)0.50.50.50.5
Propyl p-hydroxybenzoate (mg/mL)0.50.50.50.5
With this two formula, delivering 10 volunteers tests.Compliance response variables (sugariness, fruity, the mark of bitterness sensation) is recorded as 1 to 5 minute.Whether the unidirectional ANOVA method of usage data analytical data has significant difference.
Table 4 sweeting agent and the essence result on mouthfeel impact
ExperimenterPrescription 4Prescription 2Prescription 3Prescription 4
A3423
B3535
C5344
D3233
E3533
F4354
G3532
H4423
I3433
J4344
Average score3.53.83.23.4
Note: 5-mouthfeel is very good, and 4-mouthfeel is better, and 3-mouthfeel is general, the bad (*: P<.0.05) of 1-mouthfeel
In general, saccharin sodium is at concentration 0.5mg/mL, and Sorbitol (70%w/v) has preferably score when concentration is 500mg/mL.Orange taste essence is better than strawberry essence, and the sugariness of orange taste essence is little compared with strawberry essence, and has fruit-like flavour.But all formulas all have slight anesthesia sensation on tongue.P-Hydroxybenzoate odorless or have slight special aroma, mildly bitter flavor, the fiber crops of burning, so the anesthesia sense on this tongue may be from the p-Hydroxybenzoate using as antiseptic, so we adopt benzoic acid further to compare research.
Embodiment 3: comparative study
The random oral mixed suspension formula of liquid of selecting 10 volunteers to adopt one of two kinds of antiseptic of blind method research (p-Hydroxybenzoate or benzoic acid), evaluates its its sugariness, fruity, bitterness and the sensations such as anesthesia sense on tongue
The impact of table 5 antiseptic on mouthfeel
CompoundPrescription 1Prescription 2
Orange taste essence (mg/mL)11
Sorbitol 70%(w/v) (mg/mL)500500
Saccharin sodium (mg/mL)0.50.5
Methyl parahydroxybenzoate (mg/mL)0.5-
Propyl p-hydroxybenzoate (mg/mL)0.5-
Benzoic acid (mg/mL)-1.0
According to this two formulated oral liquid, deliver 10 volunteers and test.Compliance response variables (sugariness, fruity, the mark of bitterness and anesthesia sensation) is recorded as 1 to 5 minute.Whether the unidirectional ANOVA method of usage data analytical data has significant difference.
The result of table 6 antiseptic on mouthfeel impact
ExperimenterPrescription 1Prescription 1
A35
B44
C53
D45
E34
F34
G55
H44
I54
J45
Average score4.04.3
Note: 5-mouthfeel is very good, and 4-mouthfeel is better, and 3-mouthfeel is general, the bad (*: P<.0.05) of 1-mouthfeel
Generally speaking, under benzoic acid exists, do not feel the sensation of anesthesia, in the oral liquid that includes methyl parahydroxybenzoate and propyl p-hydroxybenzoate, can feel slight anesthesia sense.Table 4 is listed the compositions of the most extensively being recommended by volunteer.
The better oral liquid prescription of table 7
CompoundConcentration (mg/mL)
Paroxetine hydrochloride: Amberlite IRP-641:1
Microcrystalline Cellulose CL61130
Orange taste essence1.0
Sorbitol 70%(w/v)500
Saccharin sodium0.5
Aerosil30
Benzoic acid1.0
Add sodium hydroxide and regulate pH to 5.0.

Claims (10)

CN201410287053.6A2014-06-252014-06-25Paroxetine oral suspension and preparation method thereofPendingCN104027306A (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
CN201410287053.6ACN104027306A (en)2014-06-252014-06-25Paroxetine oral suspension and preparation method thereof

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CN201410287053.6ACN104027306A (en)2014-06-252014-06-25Paroxetine oral suspension and preparation method thereof

Publications (1)

Publication NumberPublication Date
CN104027306Atrue CN104027306A (en)2014-09-10

Family

ID=51458458

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CN201410287053.6APendingCN104027306A (en)2014-06-252014-06-25Paroxetine oral suspension and preparation method thereof

Country Status (1)

CountryLink
CN (1)CN104027306A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN106309363A (en)*2016-09-242017-01-11万特制药(海南)有限公司Paroxetine hydrochloride oral suspension and preparation method thereof
CN108926529A (en)*2017-05-252018-12-04万特制药(海南)有限公司Paroxetine hydrochloride oral administration mixed suspension and its preparation process
CN113209017A (en)*2021-06-022021-08-06上海美优制药有限公司Paroxetine hydrochloride suspension and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN1140411A (en)*1994-02-031997-01-15史密丝克莱恩比彻姆有限公司Oral liquid compositions contg. paroxetine resinate
CN1249686A (en)*1997-01-152000-04-05史密丝克莱恩比彻姆有限公司 Paroxetine preparations
CN1294512A (en)*1998-03-242001-05-09史密丝克莱恩比彻姆有限公司 Composition of paroxetine
US20100166858A1 (en)*2006-03-162010-07-01Tris Pharma, Inc.Modified release formulations containing drug-ion exchange resin complexes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN1140411A (en)*1994-02-031997-01-15史密丝克莱恩比彻姆有限公司Oral liquid compositions contg. paroxetine resinate
CN1249686A (en)*1997-01-152000-04-05史密丝克莱恩比彻姆有限公司 Paroxetine preparations
CN1294512A (en)*1998-03-242001-05-09史密丝克莱恩比彻姆有限公司 Composition of paroxetine
US20100166858A1 (en)*2006-03-162010-07-01Tris Pharma, Inc.Modified release formulations containing drug-ion exchange resin complexes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
韦超等: "《药剂学(第2版)》", 31 August 2012, 河南科学技术出版社*

Cited By (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN106309363A (en)*2016-09-242017-01-11万特制药(海南)有限公司Paroxetine hydrochloride oral suspension and preparation method thereof
CN108926529A (en)*2017-05-252018-12-04万特制药(海南)有限公司Paroxetine hydrochloride oral administration mixed suspension and its preparation process
CN113209017A (en)*2021-06-022021-08-06上海美优制药有限公司Paroxetine hydrochloride suspension and preparation method thereof

Similar Documents

PublicationPublication DateTitle
US6391886B1 (en)Oral compositions having improved consumer aesthetics
KR101551506B1 (en)Medical composition containing rebamipide
JP5775597B2 (en) Pharmaceutical composition for intranasal administration comprising mometasone furanate and azelastine hydrochloride
CN110035741B (en) Oral solutions containing atomoxetine hydrochloride and methods thereof
KR102226833B1 (en)Complex granule formulation having improved stability comprising levocetirizine and montelukast
KR20100135316A (en) Liquid preparation for diperipron with rich flavor
EP2838510B1 (en)Atomoxetine solution
CN104027306A (en)Paroxetine oral suspension and preparation method thereof
CN108430469A (en) ST-246 (tecavirin monohydrate) suspension preparation
JP2012136492A (en)Chinese oral liquid medicine improved in medicine-taking feeling
JP2003231647A (en)Oral liquid composition
TW200413027A (en)Oral liquid tolterodine composition
JP2004161679A (en) Liquid for internal use
CN101103968A (en)Ambroxol oral liquid with good taste
WO2003063856A1 (en)Jelly preparation containing branched amino acids
JP5009707B2 (en) Solution for oral administration of quinolone antibacterial agent masked with unpleasant taste
JP4216916B2 (en) Drinking liquid composition
KR102323708B1 (en)Fast dissolving granulate
CN103736098A (en)Intranasal medicinal composition containing bilastine and mometasone furoate
WO2011148794A1 (en)Dimemorfan-containing liquid preparation for internal administration
JPH10167988A (en)Oral liquid preparation
JPH1036252A (en) Belladonna (total) alkaloid-containing oral liquid
JP6794758B2 (en) Oral liquid pharmaceutical composition
CN109999201B (en) A kind of taste-masking companion agent and its application
JPH09286723A (en)Improved oral solution

Legal Events

DateCodeTitleDescription
C06Publication
PB01Publication
SE01Entry into force of request for substantive examination
SE01Entry into force of request for substantive examination
RJ01Rejection of invention patent application after publication

Application publication date:20140910

RJ01Rejection of invention patent application after publication

[8]ページ先頭

©2009-2025 Movatter.jp